News & Events about Tcr2 Therapeutics Inc.
gavo-cel Phase 2 clinical trial now focused on ovarian cancer cohort with first meaningful durability data expected in 2H 2023Second-generation enhanced programs TC-510 and TC-520 prioritized with TC-510 Phase 1 clinical trial ongoing and first meaningful objective response data expected in 2H ...
Globe Newswire
2 months ago
CAMBRIDGE, Mass., Nov. 23, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced that management will participate in a fireside chat at the 34th Annual ...
Globe Newswire
2 months ago
CAMBRIDGE, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from solid tumors, today announced the poster presentation of new preclinical data at the Society for ...
Ticker Report
5 months ago
TCR2 Therapeutics Inc. (NASDAQ:TCRR Get Rating) saw a large increase in short interest during the month of July. As of July 15th, there was short interest totalling 2,070,000 shares, an increase of 21.1% from the June 30th total of 1,710,000 shares. Approximately 7.0% of the shares of the ...
Thinking about buying stock in Draganfly, Enservco, Avinger, Hall of Fame Resort & Entertainment, or Tcr2 Therapeutics? Thinking about buying stock in Draganfly, Enservco, Avinger, Hall of Fame Resort & Entertainment, or Tcr2 Therapeutics? PR Newswire NEW YORK, March 22, 2022 NEW...